text:
Fifth PUSD high school focus of meeting
The comprehensive high schools were designed for about 2,700 kids each.
Mt. Carmel, whose student population was about 3,400 in the 2001-02 school year, saw its enrollment drop to about 2,700 after Westview opened. The two campuses are less than five miles apart.
No effect on PHS, RBHS
Enrollments at Poway and Rancho Bernardo highs, however, remain at more than 3,000. With 3,266 students, Rancho Bernardo is the second-largest campus in the county based on enrollment, behind Vista High, Collins said.
Vista High and its sister campus, Rancho Buena Vista High, are in the Vista Unified School District. Both schools are on the top-10 enrollment list but could fall off it when the Vista district finds a site for a new high school now in the planning stages.
The same goes for high schools in the Sweetwater Union High and San Marcos Unified school districts, said Collins.
"If we don't do something, we're going to be left alone up there (on the list of) the big schools," he said.
How to handle size is key
Being large is not necessarily a bad thing for a school, said Jim Esterbrooks, spokesman for the San Diego County Office of Education.
"It comes down to how the school is organized," he said. "The important thing is to make sure faculty and staff are connecting with kids. And there are a lot of ways to do it."
Creating "schools within a school" is one method used to keep students from feeling lost in the academic shuffle, Esterbrooks said. He cited Torrey Pines High, which has about 3,200 students.
Part of the San Dieguito Union High School District, the campus has divided students into "villages" in an effort to make the school seem smaller and more personal. The district has also broken ground on a new high school which will funnel students away from Torrey Pines.
Poway Unified officials said they worry, however, about their district's ability to offer all the programs students would like if local high schools remain large.
"For instance, if you're at a high school with over 3,000, you may not be able to play on one of the sports teams that you would be able to (play on) at a smaller high school," district spokeswoman Sharon Raffer said. "Or you may not be able to be an officer, in the drama club, in the school play, etc. At a smaller place, you have a better chance."
Parents against boundary changes
Recent history suggests at least some parents may agree. The high enrollments at Poway and Rancho Bernardo high schools led to parental complaints about overcrowding before Westview opened.
In anticipation of the new campus' debut, district officials proposed changes to school attendance boundaries that would have balanced enrollment at all of Poway Unified's regular high schools. The idea, which would have shifted several hundred Carmel Mountain and Rancho Bernardo teenagers to the Rancho Penasquitos high schools and some Poway High students to Rancho Bernardo, sparked so much public outcry the plan was dropped indefinitely.


text:
Hi there! Below you will find gluten free recipes so good your family can't tell the difference:
The site consists of over 300 recipes your kids will love. These recipes are so good your friends and family won't even be able to tell the difference! If there's a recipe you would like me to make gluten free, contact me.

subset: commoncrawl


text:
Talk Radio: Sharon & Brad let their hair down on the sludge of 2010 With all the focus on so-called reality this year, people are getting faker and faker, and even more bizarre. Co-Hosts Sharon Haver and Brad Boles review some of the ridiculous and stupid fads in fashion, beauty, and style. Brad's on a…Published on December 30, 2010
More On: ski clothes
Schussing for Style…
Schussing for Style…Wool makes its mark in fashionable ski clothingPublished on November 24, 2003
ibex, latest fashion, outdoor clothes, ski clothes, ski trends, winter sports clothing, wool ski clothes


text:
On every issue, we must follow the evidence where it leads and listen to people where they are. If we do that, there is no problem we cannot solve.
Beijing Goes Smoke-Free
Public Health
Politico: Inside the War on Coal
Mike Bloomberg on FDA's new regulations to remove trans fats in processed foods
Public Health
Rapid Urban Growth Requires Prompt Action
Innovative Government
Climate Action by Major Oil and Gas Companies
Prime Minister Modi's Swach Bharat - Clean India
A First-Generation College Student's Path to Yale
Latin America, Compact of Mayors & Road to Paris
Tomorrow can be better than today. And we know that it's up to us to make it so.
Give Back. There's nothing more rewarding than making a difference in other people's lives.
Philanthropy can be a powerful force for change, and I'll continue doing everything I can to leave an even better world for generations to come.
Mike Bloomberg and mayor of Paris, Anne Hidalgo
Over the next few days, leaders from cities, local governments and other organizations around the world will gather in Lyon, France...
Mike Bloomberg
I thank President Hollande for his leadership on climate change, and for working to ensure that both cities and the private sector have...
Mike Bloomberg
There is a good chance that in five months the United Nations' conference on climate change in Paris will set the world on a path to...
84 cities, representing more than 288M people & 4% of the total global population, have committed to @CompactofMayors http://t.co/me5PLcrdlH
Must read @Politico story on @MikeBloomberg, @SierraClub's Beyond Coal campaign and the future of American energy: http://t.co/uGBm1ckmGE
Mayor Eric Garcetti, City of Los Angeles, CA
The Los Angeles River was fundamental to the founding of our city and is one of our most promising assets...
Mayor Junie White, City of Spartanburg, SC
The arts are a powerful agent for change, and I am thrilled that Bloomberg Philanthropies has selected Spartanburg to participate in...
Mayor Karen Freeman-Wilson, City of Gary, Indiana
As Mayor of Gary, Indiana, I believe that public art – combined with design, community engagement, and private and government...
Mayor Kathy Sheehan of Albany, Mayor Gary McCarthy of Schenectady, and Mayor Lou Rosamilia of Troy
In our service as Mayors of the cities of Albany, Schenectady and Troy – a region encompassing approximately one million people, with...


text:
Monrovia — There were no pushing and pulling this time, no condemnation or claims of "rotten rice" from hungry and besieged West Point residents. What many witnessed Saturday was a more organized queue of West Point residents, awaiting their turn to get much-needed food aid.
Until Saturday, families and friends across the quarantine zone had been struggling to get food to the relatives as state security restricted movement in the area which, along with Dolo's Town had been declared a quarantine zone in the aftermath of a violent turn earlier during the week.
Violence struck the area Wednesday when residents set-off a revolt, which was struck down by the military officials, following a controversial government policy that seals-off the entire area in an effort to curb further spread of the deadly Ebola virus. The riots began when a commissioner was stopped from leaving the district with her family, while the rest of the residents told not to leave.
On Saturday, families and friends queue up alongside a government and United Nations distribution team to provide additional food to what the government is providing.
Some loved ones could be seen giving out potato greens, charcoal, oil, rice and other ingredients to their relatives behind the quarantine line. Girish Kurseja, an Indian businessman took three bags of rice and some water to three of his employees currently being quarantined in the community.
Kuseja told FrontPageAfrica that his employees had called to inform him that the food they are receiving are not enough to carry them through the 21-day incubation period. Based on that, he says, he decided to bring them some food to augment the government's effort. He explained that the quarantined communities should not feel that they are being punished but should see it as efforts to help save them from the deadly Ebola Virus.
"Three of my workers, they stay in West Point and because of the government' measure to quarantine West Point for 21 days, and there was no sufficient food and water in the house, so they call me to tell me and I told them not to worry I will find time to come see them."
"So I brought three bags of rice and water to them" says Kurseja. "West Point people should be appreciative that the government is prioritizing them so they should be privileged to be quarantined to avoid Ebola spreading.
The businessman said he was initially reluctant to make the trek to aid his employees because of a lot of rumors circulating that people are not allowed to see or bring anything to anybody.
Nevertheless, he says, he finally decided on Saturday to come and try if he could have access. The businessman says the security officers were very helpful and cooperative. "By the grace of God all the officers were very cooperative."
He then urged Liberians to cooperate with the quarantine measures being undertaken by the Liberian government because it is in the best interest of the country. "They should not panic, there are enough food supply and water, they just need to be patient."
Most of the residents interviewed by FrontPageAfrica said they were caught by surprise. As a result, they did not have enough time to purchase food and other basic needs. In the process, some say, even people who do not live in the community were trapped and had no means of getting home to their family after the area became a quarantine zone.


text:
Male , 26-30
Last Seen 6 days ago
Member Since Sep 12, 2009
Favorite Quote
Politics Conservative
Horoscope Aquarius
Special day
Local Time July 8th, 1:36 AM
Single Again After My Sweetheart And I Broke Up Last Night... The title says it all, and by the way, I'm sick and tired of my insecurity and my trust issue and I wish that those issues would just go away because they're NOT welcome in my life! :( [more]
1l0vesunsets has shared 3 Mature Experiences
On March 8th 2010, We Broke Up After Dating For One Day Short Of 2 Months On March 8th 2010, the girl that I was dating for at least 2 months broke-up with me. :( I'm just having the hardest time getting over her (if you want to know why that is, go ahead a… [more]
On May 22nd, 2010, I Met Another Ep Member In Person For The First Time As the title says, I met a fellow EP member (palexchick226) in person for the first time on May 22nd, 2010. Her name is Ashley and she's such a sweetheart. After our sixth time hanging out as friends … [more]
1-3 of 3 Stories


text:
See other Krakow properties
Dizzy Daisy Downtown Hostel
Real Reviews
Real reviews from fellow travellers
These are trusted reviews from guests who have actually stayed here. We hope you find them helpful.
Note: we only give a property a rating once it has received a minimum of 3 reviews.
- " Great hostel, staff was great . That not my last stay there! "
- 26 Jun 2015 Anonymous Denmark
- " I liked the place, the room was perfect. Will definitely go back. "
- 17 Jun 2015 Alberto Spain
- " Nice showers and toilets, close and central accomodation, not the greatest atmosphere but there is plenty of things to do in Kraków so it's ok :) "
- 15 Jun 2015 Emily Australia
- " It was a very good location 8 minutes to the city centre, a lot of shops around. Nice staff and clean rooms. "
- 27 Feb 2015 Anonymous Latvia
- " Staff were really helpful! Place is great value for money and felt safe when I stayed there. Wifi was a little slow, but not much of a problem. Good location. Would stay with again :) "
- 19 Jan 2015 Nicholas Australia
- " recommend it "
- 01 Jan 2015 mohamed France
- " this is my second time I stayed this hostel, I have a very good feeling about this hostel. I was not lucky this time, a group in the next room put on music so loud at 4a.m., all of us in our room did wake up. "
- 30 Oct 2014 Anonymous Japan
- " The hostel was only a 10 minute walk from the Old Town Square. The rooms were nice, clean, and the beds were comfortable. The hostel and area were quiet. The staff were so friendly and so helpful!!! I would definitely would recommend this hostel to anyone. "
- 30 Oct 2014 Anonymous Canada
- " Because of the door in between the dorm you could even hear what the people in the other dorm were talking about, which was a bit annoying. And my friend had problems entering the dorms in the morning, because the doorcodes had already been changed, but the reception claimed that the old code should still work. Other than that, it was really great staying at the hostel. The staff was very friendly, and we liked the common room very much. "
- 02 Oct 2014 Anonymous Germany
- " I thought that the staff was really helpful and the hostel was clean and a great value for the money. The only drawback is that there were some very loud people at night and I wished that the staff would have enforced the noise policy. "
- 12 Aug 2014 Anne USA


text:
"Even if the president really doesn't know anything about someone wanting to come forward, his position should be that whistle-blowers deserve protection and that anyone who has different information about Benghazi is free to come forward to Congress. The president's unwillingness to commit himself to protecting whistle-blowers only aids those in his administration who are intimidating them."
Nothing could render Obama a lame duck quicker than an Obamacare train wreck that undermines his signal legislative victory, even as revelations by Benghazi survivors point to a colossal failure by his "leading from behind" policies overseas.
— The Washington Examiner


text:
Bobbi Brown is giving shoppers 25% off from June 9th through June 11th. During the [online] Summer Shopping Event, save 25% off all Bobbi Brown products. The proceeds of each purchase will help support Bobbi Brown's $10,000 donation to Dress for Success. All orders over $60 will also be eligible for free standard shipping. Discount should automatically be reflected at checkout! (If it's not, enter coupon code SUMMER1.)
Sale ends today, so here's your reminder!


text:
Re "Women need choice of contraceptives" (Viewpoints, July 9): The information in this article regarding Hobby Lobby is faulty. Hobby Lobby did not object to contraceptives. Their objection was to health coverage for drugs that can cause the abortion of a fertilized egg. Hobby Lobby has health coverage for contraceptives that prevent conception.
It should be noted that not everyone who opposes abortion does so for religious reasons. Scientists tell us that life begins at conception and therefore, there are some who oppose abortion for ethical reasons. -- Lorraine Latreille, Sacramento


text:
SCSD 2 final Kindergarten screening
Date posted: July 31, 2014
SHERIDAN— Sheridan County School District 2 is holding a second opportunity for Kindergarten screening. All Kindergarten parents are urged to have their child attend this screening if they did not do so in April. Appointments can be made by calling 674-7405, extension 5105 no later than August 8. You can register your child for Kindergarten is Sheridan School District 2 at the screening. Parents and guardians need to bring a birth certificate and immunization records to the registration. Children must be five-years-old on or before September 15, 2014 to be eligible for Kindergarten this fall. For more information call Scott Stults at 647-7405, extension 5108.
Copyright © 2015 The Sheridan Press or Sheridan Newspapers, Inc.
Reader Comments
Tell us what you think. The Sheridan Press offers you the chance to comment on articles on Thesheridanpress.com. We power our commenting forum with facebook comments. Please take a look at our participation guidelines before posting.


text:
Our first podcast went live an hour ago.
'On Becoming Invisible' is a 70 minute exploration of drone, dark-ambient and post rock, blended together by Dundee-based artist Erstlaub who will be releasing new music with us in the next few months.
It's pretty amazing stuff. Check the podcast link and get stuck in.
Next podcast is from label head TVO and should be here in a couple of weeks…


text:
Casual & Short This is a great casual skirt, but it's too short! I'm 5"7 and wear a 12 in Express pants. I brought a large. The skirt flares but I was not a fan of the length. It should be advertised as a mini flare skirt. It's way too casual to wear at night, but suitable for running errands if you're on the shorter side. September 1, 2013
Love! This skirt is adorable. Yes it's jersey, that's what it says, but it's soft and flowy and flatters my shape beautifully! I love that it's color is nuetral enough to go with many tops. It's casual but can also be dressed up with a waist belt and some sexy heels. You just have to know how to work it! August 4, 2013
Online shopping... I thought this would be a great casual skirt for summer. It is casual - very casual. The material is described as "seductively soft jersey" - while it is more gym-short jersey. The cut and fit of the skirt are excellent. It runs true-to-size. If I had the opportunity to touch the material prior to purchasing, I would have avoided this purchase. June 27, 2013


text:
Lately I have been struggling with managing my Twitter connections, keeping faithful to my somewhat-connector beliefs while trying to identify my audience in a better, more effective way.
While I still believe you shouldn't be excessively picky on who to connect with, sometimes you really have to draw a line. I see Twitter accounts full of self-promotional links. Just that, nothing else. According to these people, the whole world of social media revolves solely around them.
Is it really worth to focus on the short-term plan, rather than the long-term, big picture?
Blogging for self-promotion
It could be pretty easy for me.
My company develops innovative marketing solutions, aiming particularly at emerging new technologies (mobile, web3d, advergames) used for promotional / marketing finalities. I could write just about this, using this blog as a mere case history of our projects and self-promotion of our products.
Would it work? Would it be interesting and engaging? I really doubt it. Maybe it could work for some other company, selling more consumer-centric products, that's for sure. But for my company, no, I really don't think so.
I tried for a while to post more technology-centric material, with good results among technology-savvy readers, industry peers sharing our same niche of market. Were they interesting people? Yes for sure. Customers? Not really, mostly because they had their own business up and running as well.
A world of opportunities
What I chose to do instead is considering my audience as something more than just a mass of customers, but an online community – and talking about audiences, I got my daily inspiration on the subject from the awesome Suzanne Vara, as it frequently happens lately.
I chose to write about stuff that interest me in first place, and that I am pretty confident will interest other people as well. But these people are probably not going to be customers either, so why do I even care?
Because your audience, any kind of audience, can be your best asset in this social media world, and perfectly complement your brand building strategy.
For my line of business, it's really hard to have a direct reader->customer approach, we're not giving away cookies after all.
So your objective, your end goal has to be something different, something not about immediately monetizing your efforts.
You really have to look at the bigger picture.
- With this blog I show that my business isn't just about my products, services or whatnot. I show it's about people, working together for a common goal;
- I respect my audience because I am not trying to sell stuff to it constantly – and by that I also mean that I don't include a sentence inviting you to ask me how can I improve your business because I rock and you really should do it;
- I realize that my audience is made of smart people who are not up for taking shit from me, they like to read interesting information but they won't blindly follow my lead.
And when you do things right (or the closest to it possible), you realize people appreciate it, like my friend Paul Castain commenting on my latest post:
Start to value your audience
It can be your best ally. Its people can turn into fans of your brand – and not just in the Facebook meaning, but on a more serious note – and then, something kinda spectacular can happen when people from that very same audience turn into a friend.
With friends met like this, funky stuff can happen.
There can be business opportunities, chances that will make every short-term monetary gain pale in comparison.
Like a marriage, your audience is good for sharing both the good and the bad moments of your (business) life. Keeping it informed, of the good and bad things, is a key element of nurturing your audience and improving your online social networking, because the bad stuff will become public sooner or later anyway.
Your business is about your customers
The point is, though, you could never know where your customers came from. Because every little step you take today – including that one that looks insignificant or even counter-productive in terms of time spent – could become the source of something completely mindblowing in weeks, months or years.
I've seen this happening many times, some act of kindness, some information shared for no "$$$ reason", just to be nice, turned into a friendship and then a business opportunities, eventually money.
Is it better to cash-in today or to plant the seeds of your business and let them grow into something amazing and unique that you really wanna be part of?


text:
Forum Menu
Daily Digest
Home Page
Post Response
weight problemPosted by: Dee Beede
Category: Medical
Posted on: August 13, 2002 at 19:24:55
We have had our Jack Russell about 3 years. She has a very bad weight problem that I'm not quite sure to do about. I have taken her to the vet and had blood work done on her and it showed no thyroid problem. But she is getting heavier and heavier. I am feeding her an all natural dog food and have had her on a weight control food from the vet but it didn't help. She really doesn't eat a whole lot. Maybe a cup a day. She is spayed if that makes a difference.She weighs about 19 lbs. Can you give me advice on what to do for her? Thanks so much.


text:
Casio Watches
The elegance it has, is valued by aesthetic individuals only. Casio stands tall when it comes to the best brands for Watches. Casio Watches are being frequently used because they are available at prices ranging from the lowest to the most expensive. Casio has brought for you both manual and digital watches so it depends on you that which one do you prefer.
Casio Edifice series is popular these days and here we have all the models of edifice series. Moreover, we have both Men's Watches and Women's Watches for you to choose from. Casio Watches are available at the best price at Symbios.pk, the largest online shopping website of Pakistan. So shop for them online and avoid shopping hassle smartly.
There are no products to list in this category.


text:
Windbreakers are a must
Luggage and bags: If you bring your own car over on the ferry, you can bring anything you want.
If you are walking bring something easy to carry on and off the boat.
Clothing/Shoes/Weather Gear: Wind breaker by kyoub
It is very windy out on the island so you will need a wind breaker. It may not be as warm as you expect either. I needed sweaters instead of light weight clothing when I was there. Be sure to check the temperature and take in the fact that the wind makes it seem colder than it sounds.
Toiletries and Medical Supplies: Most supplies are available in Penneshaw
Photo Equipment: Take a lot of film or a very large memory stick.
You will want many pictures of this island.
Miscellaneous: You can find wine of every age and color. From cheap to very expensive.
There was only one place to get on the internet and that was in Penneshaw.
- Road Trip
Warm clothing is a must, even in summer!
Luggage and bags: If you are bush camping, you don't want a suitcase at all. Put everything you need in a pack or a small duffle.
Clothing/Shoes/Weather Gear: 1) You might like a rain slicker. It rained a lot while I was there.
2) Not many changes of clothes, except, of course, clean undies and socks. You'll need one/two pair of long pants and one/two pair of shorts depending on the length of your stay.
3) Hiking boots.
4) Most importantly, bring warm clothing to layer. In the photo--click to see the full-body view--I am wearing about four layers of stuff over my upper body (and I slept wearing most of it, too). Even in summer K.I. can be quite chilly and very windy.
Toiletries and Medical Supplies: • Waterless hand washing gel
• Extra mini-packs of facial tissue (to use at the outdoor commode)
• After-bite stick (or just plain amonia) for insect bites
Photo Equipment: Lots of memory chips and batteries. You may not have outlets to recharge dead batteries.
Camping/Beach/Outdoor Gear: If you have your own sleeping bag, by all means bring it. I rented mine, but the zip was broken (maybe that's why I was so cold at night), and the stuffing was lumpy.
Miscellaneous: Chocolate, raisins, sunflower seeds or other non-crushable munchies.
Buy beer as soon as you get to the island and carry it all around in the truck with you. You never know when thirst will strike!
- 1
- Southern Ocean Lodge
- Wanderers Rest of Kangaroo Island
- Kangaroo Island Lodge
- Comfort Inn Wisteria Lodge
Show Prices
Show Prices
Show Prices
Show Prices
Instant Answers: Kangaroo Island
Get an instant answer from local experts and frequent travelers
- Great room rates
- Expedia.com
- Plenty of choices
- Agoda.com Save up to 75%, Don't miss! Live support, Instant confirmation.
Sponsored Links


text:
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure. Therefore, investigations on novel therapeutic targets are of fundamental importance. Deregulation of epigenetic mechanisms underlying chromatin modifications during stem cell differentiation has been suggested to contribute to soft tissue sarcoma pathogenesis. One of the main elements in this scenario is enhancer of zeste homolog 2 (EZH2), a methyltransferase belonging to the Polycomb group proteins. EZH2 catalyzes histone H3 methylation on gene promoters, thus repressing genes that induce stem cell differentiation to maintain an embryonic stem cell signature. EZH2 deregulated expression/function in soft tissue sarcomas has been recently reported. In this review, an overview of the recently reported functions of EZH2 in soft tissue sarcomas is given and the hypothesis that its expression might be involved in soft tissue sarcomagenesis is discussed. Finally, the therapeutic potential of epigenetic therapies modulating EZH2-mediated gene repression is considered.
Keywords:EZH2; soft tissue sarcomas; epigenetics; methylation; methyltransferases
Soft tissue sarcomas: a clinical challenge
Soft tissue sarcomas (STSs) are a group of heterogeneous malignant neoplasms thought to arise from molecular lesions occurring during the differentiation of mesenchymal stem cells (MSCs) [1]. STSs account for less than 1% of all adult tumors and for about 15% of all pediatric ones, with an estimated 10,520 new cases in the US in 2010 [2,3]. A series of chromosomal translocations have been identified as hallmarks of most STSs, such as t(X;18)(p11.2;q11.2) in synovial sarcoma, t(11;22)(q24;q12) in Ewing's sarcoma, t(2;13)(q35;q14) and t(1;13)(p36;q14) in alveolar rhabdomyosarcoma (RMS). These chromosomal rearrangements result in oncogenic fusion proteins that play direct roles in altering gene expression pattern in STS, promoting tumor aggressiveness. Because of their infiltrating behavior, only 50% of STSs are suitable for radical surgical resection. Moreover, a fraction of STSs are resistant to chemotherapeutic agents, especially the metastatic forms [4]. Doxorubicin, the drug used in standard single-agent chemotherapy protocols for the treatment of metastatic STS, results in only 20% to 25% response rates. Even the combination of doxorubicin with other agents, such as ifosfamide, has not dramatically improved the overall 5-year survival rate, which is no higher than 50% to 60% [4]. Nevertheless, chemotherapy represents the only viable strategy for palliation of symptoms in patients with metastatic disease, improving their quality of life [5]. New promising biological drugs, such as monoclonal antibodies to insulin-like growth factor receptor (IGFR), inhibitors of multityrosine kinases, and mammalian target of rapamycin (mTOR), have been introduced in STS clinical trials (Table 1) [4]. However, disease stabilization is still not seen in many patients, especially those affected by peculiar histological variants or showing poor-risk factors; it is reasonable to hypothesize that a combination of cytotoxic chemotherapy with targeted agents may be more appropriate to improve outcome in STS patients. A novel class of therapeutic targets is represented by epigenetic regulators, such as DNA methyltransferases (DNMTs), histone acetylases (HATs), histone deacetylases (HDACs), and histone methyltransferases (HMTs). Physiologically, all these enzymes work in concert for regulating gene expression by modifying the state of chromatin without altering DNA gene sequences in order to obtain a proper tissue determination. Increasing evidence demonstrates that they play key roles in human tumorigenesis, often being deregulated in terms of expression and/or activity and leading to silencing of essential regulators of cell proliferation and differentiation. Indeed, from comparative analyses, it appears that cancer genomes show different patterns of epigenetic modifications as compared to normal cells. Using inhibitory agents of all of these enzymes, it is possible to obtain pharmacological reversion of the tumor-specific gene expression profile, as well as reactivation of abnormally silenced tumor-suppressor genes in cancer cells [6]. Among these regulatory players, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) is considered one of the most appealing epigenetic targets for therapy in human cancer [7].
Table 1. Targeted therapy clinical studies for soft tissue sarcoma (STS)
The Polycomb group protein EZH2 in STS
EZH2 is one of the Polycomb group (PcG) proteins, which repress expression of developmentally regulated genes that induce tissue differentiation, such as homeotic genes. PcG proteins help maintaining the undifferentiated, multipotent phenotype of the embryonic stem cell compartment [7-11]. In vertebrates, PcG proteins form two different groups of multiprotein Polycomb repressor complexes (PRCs), PRC1 and PRC2/3. EZH2 is the catalytic unit of the PRC2/3 complex, the part involved in the initiation of gene repression. EZH2 methylates lysine 27 of histone H3, thus generating the H3K27-trimethylated epigenetic mark that is recognized by the PRC1 complex for further, long-term chromatin modifications (Figure 1a) [8]. EZH2 is promptly downregulated during progenitor cell differentiation, becoming undetectable in adult specialized cells and tissues (Figure 1b) [12]. Conversely, EZH2 is abnormally overexpressed in a wide range of tumors as compared with corresponding normal tissues, its level of expression being correlated with cancer aggressiveness [7,13,14]. Moreover, the abundance of EZH2 molecules induces the formation of more repressor complexes and, by altering the balance between different PcG components, may lead to the formation of tumor-specific PRC complexes that show differential substrate specificities [15]. As a result, not only the general level of repression but also the specificity of repressed genes is changed. EZH2 has recently been found aberrantly expressed in aggressive and poorly differentiated breast and prostate carcinomas [13,14], as well as in STS [16,17]. EZH2 aberrant overexpression may be one of the molecular lesions occurring in differentiating mesenchymal stem cells (MSCs), which are thought to be the cells of origin of STS [1]. It has been proposed that the presence of EZH2 in tumors with embryonal features and stem-cell phenotype, such as STS, may explain their undifferentiated and immature character. In view of these data, EZH2 appears to be an attractive target for investigation in STS.
Figure 1. Schematic representation of transcriptional gene repression by enhancer of zeste homolog 2 (EZH2). (A) In a mesenchymal stem cell or in a soft tissue sarcoma (STS) cell, EZH2 interacts with suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED), the other core components of the Polycomb repressor complex 2 (PRC2) complex that is involved in the initiation of gene repression. By the methyltransferase activity of EZH2, histone H3 is methylated on K27 thus generating the epigenetic mark H3K27Me3 that serves as a signal for the recruitment of PRC1 complex. PRC1 DNA binding prevents the access of antagonistic chromatin remodeling factors, such as the SWI/SNF complex, thus stabilizing the repressive state of the chromatin. The PRC2-associated activity of histone deacetylase (HDAC) and the interaction of EZH2 with DNA methyltransferases (DMNTs) allow a further compaction of chromatin by means of histone deacetylation and DNA methylation, respectively (synergism of epigenetic mechanisms). (B) During differentiation the level of EZH2 decreases with consequent reduction of PRC2 complex. H3K27 becomes hypomethylated and the SWI/SNF complex facilitates the DNA binding of tissue specific transcription factors (TF) that engage histone acetyltransferase (HAT) to allow initiation of transcription.
EZH2 in RMS
RMSs are a heterogeneous group of STSs characterized by features of skeletal muscle tissue and thought to be caused by abnormalities occurring during the course of myogenesis [18,19]. It prevalently affects pediatric patients and accounts for almost 50% of all STSs [20]. Classically, RMSs are histologically subdivided in two subtypes: the alveolar and embryonal forms. More recently, it has been reported that a diagnosis of alveolar RMS can be made only in the presence of two specific molecular aberrations, namely t(2;13)(q35;q14) and/or t(1;13)(p36;q14) chromosomal translocations resulting in PAX3-FKHR and the rarer PAX7-FKHR oncogenic fusion proteins, respectively [21]. These lesions have been found in about 20% of all RMSs and in about 70% of the RMSs with an alveolar histology [21,22]. True alveolar RMSs are often metastatic at diagnosis, show unresponsiveness to conventional therapy and have poor prognosis, the long-term survival rate being < 25% [23,24]. Fusion-negative RMSs include tumors with embryonal histology and the remaining part of RMSs with an alveolar histology [18]. Evidence for aberrant overexpression of EZH2 in RMS samples has been reported by Wang and colleagues [25] and by our studies in RMS cell lines and primary samples [16]. We have recently confirmed this finding in a large cohort of RMS specimens, documenting that overexpression of EZH2 is a hallmark of RMS, independently of the histological subtype [26]. It remains to be determined whether the level of EZH2 expression correlates with the presence of fusion proteins typical of the alveolar subtype. These results are consistent with the observation that in a physiological context EZH2 inhibits muscle differentiation of normal myoblasts by silencing muscle-specific genes [27]. Among these genes are those encoding for promyogenic microRNAs, such as miR-214 and miR-29. These belong to a class of small RNAs that inhibits the translation of selected mRNAs thus preventing their protein expression [25,28]. Mir-26a is another microRNA acting to post-transcriptionally repress EZH2 in normal myoblasts undergoing differentiation (Figure 2a left panel) [29]. During differentiation, miR-29 is induced and targets the PcG transcription factor yin yang 1 (YY1) mRNA promoting its degradation (Figure 2a left panel). In the absence of a myogenic stimulus and in RMS cells, EZH2 is recruited together with HDAC1 by YY1 to repress transcription of both myofibrillary genes [27,30] and miR-29 (Figure 2a right panel) [25]. Similarly, miR-214 is directly repressed by EZH2 in undifferentiated committed myoblasts and, in turn, it is able to bring about negative feedback on EZH2 during myogenesis by targeting its transcript [28]. A role for miR-26a and miR-29 in RMS pathogenesis was confirmed by recent studies [16,25]. We found that miR-26a is aberrantly downregulated in RMS cell lines and primary tumors as compared to non-tumor counterparts, and that miR-26a loss of expression is paralleled by an overexpression of EZH2 [16]. Similarly, miR-29 levels are reduced in tumor samples as compared with control muscle tissues. This finding can be interpreted considering that overexpressed EZH2 and YY1 are capable to repress miR-29 transcription in RMS cells (Figure 2a) [25]. In agreement with the above observations, it has been found that mi-R29 ectopic expression promotes RMS cell-cycle arrest, myogenic cell differentiation and tumor growth inhibition in a xenograft model [25]. Reduction of miR-29 levels had been previously reported in a small cohort of alveolar RMS [31]. Altogether, these findings provide evidence for a key role of EZH2-mediated epigenetic changes in RMS pathogenesis, which involve also mutual interactions with microRNAs.
Figure 2. Possible mechanisms of deregulation of enhancer of zeste homolog 2 (EZH2) in soft tissue sarcoma (STS). (A) In normal differentiating myoblasts (left panel) promyogenic miR-26a and miR-29 are normally expressed. MiR-26a and miR-29 target EZH2 and yin yang 1 (YY1) mRNAs, respectively, at the 3' untranslated region (UTR) to induce their degradation. Conversely, in rhabdomyosarcoma (RMS) cells (right panel) promyogenic miRNAs are downregulated and their loss of function is paralleled by the overexpression of EZH2 and YY1. YY1 recruits EZH2 to repress the expression of miR-29, establishing a negative regulatory feedback loop. (B) In synovial sarcoma, the chimerical transcription factor SYT-SSX engages EZH2 that leads to H3K27 trimethylation silencing tumor suppressor genes such as early growth response 1 (EGR1). (C) In Ewing's sarcoma the chimerical transcription factor Ewing sarcoma (EWS)/Friend leukemia integration 1 (FLI1) directly contributes to the maintenance of high level of expression of EZH2.
EZH2 in synovial sarcoma
Synovial sarcoma is a malignant cancer that affects prevalently young patients and represents almost 10% of all STSs [32]. It is characterized by the typical translocation t(X;18)(p11;q11) that generates the fusion between the synovial sarcoma translocation, chromosome 18 (SS18 or SYT) gene on chromosome 18 and either synovial sarcoma, X breakpoint 1, 2 or 4 (SSX1, SSX2 or SSX4) genes on the X chromosome [33]. Previously reported data showed that chimerical proteins SYT-SSX might disrupt gene expression mechanisms by functionally interacting with PcG proteins in synovial cells [34]. In particular, SYT-SSX2 fusion protein induces downstream target-gene deregulation through epigenetic mechanisms [35]. Recently, EZH2 has been found to mediate the effects of SYT-SSX activity. Specifically, SYT-SSX2 represses the expression of the tumor suppressor gene early growth response 1 (EGR1), a regulator of cell cycle, engaging EZH2 on the EGR1 promoter in synovial sarcoma cells (Figure 2b). EGR1 repression has been found to be associated with H3K27 trimethylation, and EZH2 and the PRC1 component BMI1 have been shown to directly bind its promoter, thus supporting the existence of a novel epigenetic mechanism of oncogenesis in synovial sarcoma [36]. This finding illustrates how a genetic lesion that generates an oncogenic trascriptional regulator might exploit EZH2 and other epigenetic regulators to sustain tumorigenesis.
EZH2 in Ewing's sarcoma
Ewing's sarcoma is an embryonal malignancy characterized by the t(11;22)(q24;q12) translocation which generates chimerical Ewing sarcoma (EWS)/ETS fusion transcription factors. One of the most common fusion protein found in patients affected by this tumor is EWS/Friend leukemia integration 1 transcription factor (FLI1) [37]. EZH2 is expressed at high levels in Ewing's tumors [17]. Studying the influence of EZH2 downregulation on gene expression, Richter and colleagues found that EZH2 is responsible for the undifferentiated phenotype of Ewing's sarcoma by maintaining a stemness gene expression signature, inhibiting differentiation [17]. Strikingly, EWS/FLI1 has been found to induce the expression of EZH2 by direct binding to its promoter in both Ewing's sarcoma cell lines and human MSCs (Figure 2c) [17]. EWS/FLI1-dependent activation of EZH2 seems to be specific, because the other components of the PRC2/3 complex are not affected [38]. Notably, human MSCs seem to represent a permissive environment for the expression of EWS/FLI1, which induces features in these cells that recapitulate Ewing's sarcoma biology. This observation may implicate EZH2 as a coinitiator of Ewing's sarcoma [39]. Data from these studies offer an example of how a translocation-derived fusion product takes advantage of EZH2 recruiting this methyltransferase to drive tumor progression at the expenses of differentiation.
Concluding remarks and future perspectives
Pediatric STSs, especially those metastatic at diagnosis, are highly aggressive tumors for which there is still an unmet medical need of more effective and less toxic therapeutic approaches. The role of the epigenetic regulator EZH2 in maintaining the embryonal cell phenotype of STS, its overexpression in these cancers and its functional interaction with many fusion proteins typical of STS, suggest that EZH2 may represent both a potential marker of undifferentiated precancerous cells and a reasonable candidate therapeutic target in STS. Increasing attention is focusing on epigenetic therapies that have provided promising results in clinical trials for some human tumors [40-42]. The clinical effectiveness of epigenetic therapies in human malignancies has been recently proved by the observation that, in a randomized phase III trial, the DNA hypomethylating agent azacytidine prolonged overall survival of myelodysplastic syndrome (MDS) patients compared to other standard therapies [43]. The potential efficacy of epigenetic therapy in STS is supported by preclinical studies employing HDAC inhibitors [36,44-46]. Many studies on cell culture and animal models indicate that diverse epigenetic processes synergize to control gene expression. Hence, different kinds of epigenetic drugs, such as DNA-demethylating agents and HDAC inhibitors, have been included in combination treatment protocols [40,47]. It is noteworthy that, in Ewing's sarcoma cells, HDAC inhibitor treatment in vitro induces downregulation of EZH2 [17], as more recently confirmed in glioma [48], gallbladder carcinoma [49] and acute myeloid leukemia [50]. Consistently, in preclinical models of different cancers, the antitumor effect of EZH2 inhibition, obtained through the methyltransferase inhibitor 3'-deazanoplanocin (DZNep), is enhanced by addition of HDAC inhibitors [51-53]. DZNep has been shown to act by causing depletion of PRC2 subunits with subsequent reactivation of PRC2-silenced genes [54,55]. In addition, it has been shown that the repressive function of EZH2 on gene expression is strengthened by the role of DNMTs, with which EZH2 physically interacts regulating their activity [56]. In this view, additional usage of DNMTs inhibitors in protocols targeting EZH2 might improve response in some tumor contexts. In turn, since HMTs are also active in non-proliferating cells, the inclusion of EZH2 inhibitors in combination regimens may overcome the ineffectiveness of DNMTs inhibitors in quiescent cells. On the other hand, it must be noted that, due to the complexity of molecular crosstalk involved in epigenetic control, the use of epigenetic drugs affecting a variety of molecular networks entails the risk of unforeseeable effects. For instance, despite their antiproliferative effects in vitro, treatments employing either HDACs or DNA methylation inhibitors have been recently reported to increase in vivo the invasive capabilities of RMS cells through upregulation of the prometastatic gene Ezrin [57]. Major questions remain open on the in vivo mechanism(s) of action of epigenetic drugs. Indeed, the clinical response to azacytidine in terms of prolongation of survival in MDS patients does not appear to be directly correlated with methylation of specific tumor suppressor genes, though methylation status has been shown to correlate with poor survival [58]. Even if future preclinical studies will better clarify the mechanisms of action of these drugs on gene expression, preclinical findings will need to be validated in humans [59].
Despite these unresolved questions, epigenetic therapy is a promising approach for targeted anticancer therapies in pediatric STS. Available evidence suggests that targeting the methyltransferase EZH2 may be potentially able to restore physiological patterns of gene expression in pediatric STS. In the future, modulation of EZH2 activity may provide a new line of intervention that could be combined with epigenetic drugs acting on other molecular targets and/or conventional cytotoxic agents to treat these aggressive pediatric tumors.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RC and RR contributed equally to selection and discussion of the literature and the conception and preparation of the manuscript. FL, AG and LM contributed to the discussion on clinical implications and reviewed the manuscript. All authors read and approved the final manuscript.
The present work was supported by grants from Ministero della Sanità Italia (Ricerca Corrente), Associazione Italiana per la Ricerca sul Cancro (AIRC Project 10338) and Istituto Superiore di Sanità (ISS Project 70BF/8) to RR and by grants from Ministero della Salute, Italia (Ricerca Corrente) and AIRC (Special Project 5 × mille) to FL.
Siddiqi S, Mills J, Matushansky I: Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas.
Curr Stem Cell Res Ther 2010, 5:63-73. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010.
CA Cancer J Clin 2010, 60:277-300. PubMed Abstract | Publisher Full Text
Vincenzi B, Frezza AM, Santini D, Tonini G: New therapies in soft tissue sarcoma.
Expert Opin Emerg Drugs 2010, 15:237-248. PubMed Abstract | Publisher Full Text
Ganjoo KN: New developments in targeted therapy for soft tissue sarcoma.
Curr Oncol Rep 2010, 12:261-265. PubMed Abstract | Publisher Full Text
Krikelis D, Judson I: Role of chemotherapy in the management of soft tissue sarcomas.
Expert Rev Anticancer Ther 2010, 10:249-260. PubMed Abstract | Publisher Full Text
Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future.
Nat Rev Drug Discov 2006, 5:37-50. PubMed Abstract | Publisher Full Text
Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Mutat Res 2008, 647:21-29. PubMed Abstract | Publisher Full Text
Sparmann A, van Lohuizen M: Polycomb silencers control cell fate, development and cancer.
Nat Rev Cancer 2006, 6:846-856. PubMed Abstract | Publisher Full Text
Ringrose L, Paro R: Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins.
Annu Rev Genet 2004, 38:413-443. PubMed Abstract | Publisher Full Text
Rajasekhar VK, Begemann M: Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective.
Stem Cells 2007, 25:2498-2510. PubMed Abstract | Publisher Full Text
Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins.
Cell 2007, 128:735-745. PubMed Abstract | Publisher Full Text
Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T: Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres.
Embo J 1997, 16:3219-3232. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Proc Natl Acad Sci USA 2003, 100:11606-11611. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer.
Nature 2002, 419:624-629. PubMed Abstract | Publisher Full Text
Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation.
Proc Natl Acad Sci USA 2005, 102:1859-1864. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A: Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.
Cell Cycle 2009, 8:172-175. PubMed Abstract | Publisher Full Text
Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S: EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.
Proc Natl Acad Sci USA 2009, 106:5324-5329. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P: Molecular and cellular biology of rhabdomyosarcoma.
Future Oncol 2009, 5:1449-1475. PubMed Abstract | Publisher Full Text
Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
Cancer Lett 2009, 279:126-136. PubMed Abstract | Publisher Full Text
Merlino G, Helman LJ: Rhabdomyosarcoma--working out the pathways.
Oncogene 1999, 18:5340-5348. PubMed Abstract | Publisher Full Text
Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O: Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
J Clin Oncol 2010, 28:2151-2158. PubMed Abstract | Publisher Full Text
Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ: Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.
J Clin Oncol 2010, 28:1240-1246. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Cancer Res 2006, 66:6936-6946. PubMed Abstract | Publisher Full Text
Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG, Ladanyi M: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J Pathol 2007, 212:143-151. PubMed Abstract | Publisher Full Text
Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.
Cancer Cell 2008, 14:369-381. PubMed Abstract | Publisher Full Text
Ciarapica R, Pezzullo M, Verginelli F, Boldrini R, Sio LD, Stifani S, Giordano A, Rota R: Abstract #3417: Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric rhabdomyosarcoma. In AACR Meeting Abstracts. American Association for Cancer Reasearch, Philadelphia, PA; 2010.
Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V: The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
Genes Dev 2004, 18:2627-2638. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells.
Mol Cell 2009, 36:61-74. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Wong CF, Tellam RL: MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis.
J Biol Chem 2008, 283:9836-9843. PubMed Abstract | Publisher Full Text
Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC: NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes.
Mol Cell Biol 2007, 27:4374-4387. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M: MicroRNA expression signature of human sarcomas.
Oncogene 2008, 27:2015-2026. PubMed Abstract | Publisher Full Text
Okcu MF, Despa S, Choroszy M, Berrak SG, Cangir A, Jaffe N, Raney RB: Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy.
Med Pediatr Oncol 2001, 37:90-96. PubMed Abstract | Publisher Full Text
Jain S, Xu R, Prieto VG, Lee P: Molecular classification of soft tissue sarcomas and its clinical applications.
Int J Clin Exp Pathol 2010, 3:416-428. PubMed Abstract | PubMed Central Full Text
Soulez M, Saurin AJ, Freemont PS, Knight JC: SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex.
Oncogene 1999, 18:2739-2746. PubMed Abstract | Publisher Full Text
de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, Meltzer PS, van Kessel AG: The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
Cancer Res 2006, 66:9474-9482. PubMed Abstract | Publisher Full Text
Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO: Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Cancer Res 2008, 68:4303-4310. PubMed Abstract | Publisher Full Text
Erkizan HV, Uversky VN, Toretsky JA: Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Clin Cancer Res 2010, 16:4077-4083. PubMed Abstract | Publisher Full Text
Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Muller-Tidow C, Richter GH: Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
Cell Cycle 2009, 8:1991-1996. PubMed Abstract | Publisher Full Text
Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, Stamenkovic I: EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Cancer Res 2008, 68:2176-2185. PubMed Abstract | Publisher Full Text
Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A: Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Ann Hematol 2010, 90:379-387. PubMed Abstract | Publisher Full Text
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Vigil CE, Martin-Santos T, Garcia-Manero G: Safety and efficacy of azacitidine in myelodysplastic syndromes.
Drug Des Devel Ther 2010, 4:221-229. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Lancet Oncol 2009, 10:223-232. PubMed Abstract | Publisher Full Text
Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP: Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Clin Cancer Res 2003, 9:5749-5755. PubMed Abstract | Publisher Full Text
Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.
Int J Cancer 2005, 116:784-792. PubMed Abstract | Publisher Full Text
Hurtubise A, Bernstein ML, Momparler RL: Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells.
Cancer Cell Int 2008, 8:16. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE: Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood 2009, 114:2764-2773. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Orzan F, Pellegatta S, Poliani L, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G: Enhancer of Zeste 2 (Ezh2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M, Nakanuma Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Cancer Sci 2010, 101:355-362. PubMed Abstract | Publisher Full Text
Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN: Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
Cancer Biol Ther 2009, 8:939-950. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Hayden A, Johnson PW, Packham G, Crabb SJ: S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Kalushkova A, Fryknäs M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F, Jernberg-Wiklund H: Polycomb target genes are silenced in multiple myeloma.
PLoS One 2010, 5:e11483. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Blood 2009, 114:2733-2743. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Genes Dev 2007, 21:1050-1063. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Wicha MS: Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
Breast Cancer Res 2009, 11:108. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F: The Polycomb group protein EZH2 directly controls DNA methylation.
Nature 2006, 439:871-874. PubMed Abstract | Publisher Full Text
Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G: Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.
PLoS One 2010, 5:e12710. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Herman JG, Gore S, Mufti G, Fenaux P, Santini V, Silverman L, Seymour J, Griffiths E, Caraway H, MacBeth K, Mckenzie D, Backstrom J, Beach CL: Abstract #4746: Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial. In AACR Meeting Abstracts. American Association for Cancer Reasearch, Philadelphia, PA; 2009.
Tuma RS: Epigenetic therapies move into new territory, but how exactly do they work?
J Natl Cancer Inst 2009, 101:1300-1301. PubMed Abstract | Publisher Full Text
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
New Eng J Med 2002, 347:472-480. PubMed Abstract | Publisher Full Text
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol 2008, 26:626-632. PubMed Abstract | Publisher Full Text
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 2006, 368:1329-1338. PubMed Abstract | Publisher Full Text
Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A: Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma.
George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
J Clin Oncol 2009, 27:3154-3160. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Keohan ML, Morgan JA, D'Adamo DR, Harmon D, Butrynski JE, Wagner AJ, Schwartz GK, Maki RG, Demetri GD, George S: Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008::10533.
Maki RG, Keohan ML, Undevia SD, Livingston M, Cooney MM, Elias A, Saulle MF, Wright JJ, D'Adamo DR, Schuetze SM, Sorafenib Sarcoma Study Group: Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008::10531.
Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. In ASCO Meeting Abstracts. Volume 26. American Society of Clinical Oncology, Alexandria, VA; 2008::10532.
Bertuzzi A, Stroppa EM, Secondino S, Pedrazzoli P, Zucali P, Quagliuolo V, Comandone A, Basso U, Soto Parra HJ, Santoro A: Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. In ASCO Meeting Abstracts. Volume 28. American Society of Clinical Oncology, Alexandria, VA; 2010::10025.
Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
J Clin Oncol 2009, 27:3126-3132. PubMed Abstract | Publisher Full Text
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Clin Cancer Res 2009, 15:5910-5916. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN: A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: A study of the mayo phase 2 consortium (P2C).
Richter S, Pink D, Hohenberger P, Schuette H, Casali PG, Pustowka A, Reichardt P: Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. In ASCO Meeting Abstracts. Volume 28. American Society of Clinical Oncology, Alexandria, VA; 2010::10038.
Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Wages DS, Bedrosian CL, Rubin EH, Tolcher AW: Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669).
Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D'Amato GZ, Blay JY, Loewy J, Kan R, Demetri GD: Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial.
Drugs R&D 2010, 10:165-178. PubMed Abstract | Publisher Full Text
Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Lancet Oncol 2010, 11:129-135. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Patel S, Pappo A, Crowley J, Reinke D, Eid J, Ritland S, Chawla S, Staddon A, Maki R, Vassal G, Helman L, Sarcoma Alliance for Research and Collaboration: A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
J Clin Oncol 2009, 27:5800-5807. PubMed Abstract | Publisher Full Text
Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S: Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.
Curr Opin Mol Ther 2010, 12:361-371. PubMed Abstract
Pre-publication history
The pre-publication history for this paper can be accessed here:


text:
Comment: Re:Lik-Sang (Score 1) 51 51
by dmauro (#14867163) Attached to: Hundreds Line Up For DS Lite
I didn't view it so lightly. It was extortion. They waited until I could not pre-order anywhere else before issuing their ultimatum: buy for more than the agreed price or don't get your DS. They will never again get my business.


text:
1300 369 206
...to our passionate and committed organisation.
As a young mother and nurse, I loved the flexibility of Agency work but was constantly disappointed by the lack of empathy and care for both nurses and clients. Putting our nurses first was my founding vision and I believe it is because of this we are now the Largest Nurse Owned Agency in Australia.
Read More
...because everything is done from a Nurse's perspective.
Clients love our caring personnel because we do everything from a Nurse's perspective. Each of our 4000+ members are personally selected through a face to face interview for their nursing skill, warmth and compassion.
...the difference is 'Nursing is our life!'
Most of our internal staff are Nurses or Carers with a passion for supplying only the best personnel. Nursing isn't just a job, we understand this and invite you to join our family.
...Our Patented, Simple Software gives you Freedom, Flexibility and Control.
Early on we realised that to improve our organisation, we needed better technology. Now we have our own, always online system that our Nurses love using to enter their availibities, select shifts and submit their timesheets. Additionally our clients enjoy simultaneously managing staff, entering shift requirments or checking staff compliances. This software is available for iPhone, Android and Computer Desktop, all free through Caring for You.
...for both Casual and permanent Positions.
Our recruitment process is extensive, selecting only the highest quality of nurses and carers. Thusly we excel at finding the perfect nurse for every position and facility, guaranteeing a the ideal fit between nurse and client.
...Having Fun is important too!
We believe in a good work/life balance and that's why we have a number of social events every year. It's a great way for our clients and nurses to get to know one another and helps strengthen our working relationships.
...make your trip to Australia your experience of a lifetime.
One of the greatest benefits of being a nurse is the ability to grow, experience and learn around the world. We have plenty of career opportunities for potential candidates to see the world and explore Australia while you work!
...We provide regular, free upskilling and training refreshers for our nurses and carers.
Continuous improvment is crucial in the health industry and we have dedicated, qualified educators who deliver customised online and face to face education to our nurses for our clients.
We provide an extensive range of high quality services to suit our clients from acute nursing to aged care to health software solutions.
Every time I visit one of our aged care client's homes and see them enjoying the
nurturing care of our staff I am overwhelmed by the benefits of in home care and
the reasons we should all have the opportunity to preserve our independence.
Casual Agency work is a fun, flexible way to develop new skills and relationships in the health Industry. Register now if you're interested in joining our friendly team!
Register your interest for future full time, part time & Short Term Contracts employment.
View current full time employment and contract opportunities.
Caring4U IT Solutions creates business software solutions for the various services
industries. We use web services technology and service-oriented architecture to
deliver comprehensive, industry-specific enterprise software.
Louise Thomson founder - ceo
Although we have become the largest Nurse Owned Agency in Australia with over 2500 nurses and carers, this was never my original goal. I believe it is only because of our amazing staff, technological prowess and the high number of referrals that has established us where we are today.
Since I established Caring for You in 2004 we have grown to provide healthcare personnel to Public and Private Hospitals, Aged Care Facilities, Universities, Corporations, Industry and Private Homes.
Our temporary, contract and permanent placement services include all aspects of healthcare; acute and general care, education, training, accreditation and occupational health and safety. Additionally we also provide beautiful and compassionate comprehensive in home nursing care.
To guarantee we provide the best personnel and service, the Caring for You staff are predominately nursing professionals who genuinely understand and care about your needs. All nurses and carers are individually interviewed face to face, tested for their medical expertise and experience, recruited for their kindness and compassion.
Read More
download apps now
for your iPhone or Android Phone
© Copyright ENTIRE SOFTWARE
Pty Ltd. 2013. All Rights Reserved.


text:
Back by: dongie on November 21, 2012 08:23 AM
Kim Seo-hyeong's imitation of Sharon Stone was a hit.
Kim showed off her perfect body in the scene where she imitates Sharon Stone.
Kim was chosen as a gym model for her beauty and looks in the MBC sitcom "What's A Mom?" She wore a tight black fitness suit that showed her curves and her toned complexion was enough to turn heads.
In the role of Mo Ga-bi in the SBS drama"Salaryman"in April,Kim Seo-hyeong's imitation of Sharon Stone came back up in the radar.
Her thick make up and black dress with white fur created an elegant and snobbish atmosphere about her. The way she sat with her legs crossed showed off her legs and managed to get herself out of trouble by dominating the prosecutors.
Netizens say, "The Sharon Stone parody was amazing", "Kim Seo-hyeong's sexiness and charisma is almost as overwhelming as Sharon Stone herself!" and more.
Source from :boom.seoul.co.kr
ActressKim Seo-hyeongis starring in the KBS 2TV drama"Assembly".She takes on the role of Hong Chan-mi and is expected to take the intensity up a notch.Hong Chan-mi was a law firm lawyer until she became a newly elected member of Assembly."Assembly"is a huma..... by hwarang
As the subtitle helpfully notes,"Late Spring"is the time of year when people try to convince themselves that it's not really summer yet. That's certainly true for Joon-goo (played byPark Yong-woo). The year is 1969, the dictatorship is in full swing, and Joon-goo, an..... by desire
Son Ye-jin(pictured above) and many other actresses on the Red Carpet at the 51st Annual Grand Bell Awards (Daejong Film Awards) 2014, which is also known as the Grand Bell Awards.Nam Bo-raLee HoneyJeong Jae-yeonCheon Woo-heeOh Yoon-ahKim So-hyeon-IKim Go-eun-IJo Yeo-jeongLim ..... by heej0130
"Late Spring"Genres: Drama and RomanceRunning Time: 102 min.Directed by:Jo Geun-hyeonStarring:Park Yong-woo,Kim Seo-hyeong,Lee Yoo-youngSynopsis: Joo-goo, a renowned sculptor, is diagnosed with a progressive disorder that will paralyze his body slowly. He gives up in..... by hansukj
Korean movies opening today 2014/11/20 in Korea: "Dad for Rent","Late Spring","Mot", and "He Who Loves the World""Dad for Rent" (2013)Directed byKim Deok-sooWithKim Sang-kyeong,Moon Jeong-hee,Chae Jeong-an,Jo Jae-yoon,Minah,Cho..... by asianlook
Added new poster, stills and release date for the upcoming Korean movie"Late Spring"(2014)Directed byJo Geun-hyeonWithPark Yong-woo,Kim Seo-hyeong,Lee Yoo-young,Joo Yeong-ho,Yoon Ye-hee,Ahn Soo-bin,...SynopsisIn post war Korea, the government decides to dispatch troo..... by jaicoree
Added new official trailer, posters and press photos for the upcoming Korean movie"Late Spring""Late Spring"(2014)Directed byJo Geun-hyeonWithPark Yong-woo,Kim Seo-hyeong,Lee Yoo-young,Joo Yeong-ho,Yoon Ye-hee,Ahn Soo-bin,...SynopsisIn post war Korea, the g..... by hwarang
The movie"Late Spring"has been invited to the Tokyo International Film Festival in the non-competitive World Focus division."Late Spring"was invited to the Santa Barbara International Film Festival in January in the World Premier International Competition a..... by desire
When looking at the style of women that are popular in Korean drama and considering the types of roles women usually get, it is obvious that being pretty and sweet are qualities favored. However, it takes all kinds of characters to create a work and there are many types of wom..... by dongie
Cinematographer Kim Jung-won (left) and actressLee Yoo-youngat the Milano International Film Festival. (photo courtesy of Studio Hook)The drama"Late Spring"has won awards in a series of international film festivals across the world.The film won Best Acting Performanc..... by laplace
We welcome your comments, but please be civil, DO NOT SPAM ON TOPIC. Comments deemed inappropriate will be removed and repeat will banned. Commention is a provilege that will be revoked for violations od our Comment Policy .
Comments from our old comments platform are still in the process of moving over. If you notice any comments missing they will likely re-appear soon. Thnk you for your patience.


text:
1970 plymouth duster 340 automatic -- original engine completely restored red w red interior -- bench seat-- Tach Jeffco Ent. -- 2111 E Bremer Ave Waverly,IA 319-352-2511 or 319-230-5463 ... More
Up for sale in our Ft. Lauderdale Showroom is this beautiful and monstrous example of pure American Muscle the 1970 Plymouth Duster 340. Built... More
For sale is a 1970 Plymouth Duster 340 located in our Indianapolis Showroom. In 1970 Plymouth hit a home run with a budget priced... More
1970 Plymouth 340 ``Duster`` 2 Dr. Hardtop restoration in factory color ``Rallye Red`` finish freshened, and still like new. The correct ``Rallye Red``... More
NEVADA CLASSIC CAR DEALER #40339 , VIN # VS29H0B344522 THIS IS THE CAR I ALWAYS WANTED IN HIGH SCHOOL... AND THIS ONE IS SO CLEAN... More
This 1970 Plymouth Duster has a 340ci (275 hp) V8 w/ Edelbrock 4BBL, A833 4 Speed Manual Transmission, 10 Bolt Rear w/ 3.23:1 Ratio,... More
1970 Plymouth Duster VIN VL29B0R214594 This is a rust-free North Carolina car. Operator's manual and radio manual are included in the sale. Mechanics... More


text:
Ethernet drivers installation through run script
Created: 26 Oct 2012 • Updated: 26 Oct 2012
We using deployement solution 7.1
We capture DELL 390 model desktop image and tried to deploy on in this case image gets deployed successfully but ethernet drivers not getting installed.
We deployed HP model image on DELL 390 desktop using deploy anywhere option but still ethernet drivers not installed.
Drivers are already added in drivers database.
There is one option after deploying the image we can install drivers through run script.
Can anyone know how to make such script and when i run this script
Discussion Filed Under:


text:
Despite decades of efforts to restore and protect the Great Lakes, dozens of old power plants still are allowed to kill hundreds of millions of fish each year by sucking in massive amounts of water to cool their equipment.
Records obtained by the Tribune show that staggering numbers of fish die when pulled into the screens of water intake systems so powerful that most could fill an Olympic swimming pool in less than a minute. Billions more eggs, larvae and juvenile fish that are small enough to pass through the screens are cooked to death by intense heat and high pressure inside the coal, gas and nuclear plants.
Then the water is pumped back into Lake Michigan and the other Great Lakes up to 30 degrees hotter, encouraging the growth of oxygen-depleting algae that kills fish and fouls beaches.
Known as "once-through" cooling, the process is banned at new power plants. But for nearly four decades, federal and state environmental regulators largely have ignored the issue at old plants, even as fish populations decline sharply throughout the lakes and states spend millions of taxpayer dollars to stock the waters with game fish.
Cooling intakes kill fish prized by anglers and sold in supermarkets, along with many more smaller fish and other aquatic organisms that those species depend on for food. Critics compare the outdated technology to the Bass-o-Matic, the fish-pureeing prop from an old "Saturday Night Live" sketch.
"These plants are consistent killers, plain and simple," said Frank Reynolds, a commercial fisherman on Lake Erie who since the 1970s has been showing up at public meetings with a jar of walleye larvae to draw attention to the issue. "They're trying every way they can to avoid doing something to protect the fish."
The Tribune obtained thousands of pages of industry reports documenting power plant fish kills through Freedom of Information Act requests to the eight Great Lakes states and the U.S. Environmental Protection Agency. Michigan and New York provided only limited information, while Indiana failed to respond in time to be included in this story, but the available records highlight a threat to the Great Lakes ecosystem that has largely gone unaddressed for years.
Among the findings:
•The fish killed at the Point Beach nuclear plant north of Manitowoc, Wis., reduce the yield of Lake Michigan's fisheries by an estimated 10,625 pounds a year, or about 4.5 percent of the annual commercial fishing catch by weight.
•Across Lake Michigan from Chicago, the Cook nuclear plant near Benton Harbor, Mich., kills more than 1.3 million fish annually, most of which are yellow perch. An additional 196 million eggs and other organisms die each year inside the plant's cooling system. In Waukegan, the lone Illinois power plant on the lake kills up to 5.2 million fish a year.
•On Lake Erie, the Bay Shore coal plant near Toledo, Ohio, kills 46 million adult fish and more than 2.4 billion eggs, larvae and young fish each year in the region's most prolific spawning grounds. Less than 15 miles away, the Monroe coal plant in Michigan each year kills more than 25 million fish and 499 million eggs and other organisms on the western edge of the lake.
Federal law requires new power plants to install less-destructive equipment such as cooling towers, which act like a car's radiator and draw water only to make up for what is lost through evaporation. At the Nine Mile Point nuclear plant on Lake Ontario in New York, a reactor that has a once-through cooling system killed 154,541 fish in 2007, but a second reactor with a cooling tower killed just 34,128, documents show.
Industry lawsuits have delayed the phaseout of once-through cooling at older plants. Echoing their arguments about tougher air-pollution rules, power company lobbyists say the expense would force dozens of plants to close, costing jobs and making the nation's electrical grid less reliable. Some plants have tried to reduce fish kills by building intakes offshore away from spots where fish congregate. Others have installed systems designed to deter fish with sound or air bubbles.
"It's not clear to me scientifically that there is a broad-based problem out there that needs to be fixed," said C. Richard Bozek, director of environmental policy for the Edison Electric Institute, a trade group for energy companies. "There are situations out there that need to be addressed, but those decisions should be made on a site-by-site basis."
When Congress passed the Clean Water Act in 1972, lawmakers included a provision intended to help restore the Great Lakes and other U.S. lakes and rivers by forcing polluters to significantly reduce their water withdrawals. Faced with a court order, the Obama administration in March proposed new nationwide rules that will require older power plants either to meet certain limits on fish kills or to reduce the velocity of their water intakes.
However, the EPA would leave enforcement to state officials who have allowed cooling intakes to be used with few if any limits. The proposed rules also exempt companies from installing cooling towers at older plants when they are modified.
Nearly 60 percent of facilities affected by the federal proposal probably won't be required to make any changes, according to EPA documents. Agency officials are taking public comments until July 16 and expect to finalize the rules by July 2012.
"This proposal is a big disappointment — a punt to states that have neither the expertise nor the political will to take this on effectively," said Thomas Cmar, an attorney with the Natural Resources Defense Council.
State regulators say they are doing the best they can with insufficient resources and conflicting guidance from federal officials. The EPA declined requests for interviews with Administrator Lisa Jackson or other top officials, but in response to written questions, the agency said its proposal "establishes a strong baseline level of protection and then allows additional safeguards for aquatic life to be developed through a rigorous site-specific analysis."
Millions of Great Lakes fish killed in power plant intakes
Industry resists alternative cooling equipment that would protect species
- 1
- 2
- next
- | single page
- 1
- 2
- next
- | single page


text:
Create Account
Sign In
Friday July 03, 2015
Quick Find
Use keywords to find an event.
Or perform an
Advanced Search
Event Categories
Autocross (117)
Banquet/Dinner (3)
Club Meetings (2)
Conventions (1)
Cruises and Tours (4)
Drag Racing (1)
Drifting (6)
Driving Schools (9)
Gimmick Rally (2)
Hillclimb/Time Trial (9)
Open Track/HPDE (16)
RallyCross (7)
Road Racing (27)
Shows/Concours (8)
Swap Meets (4)
TSD Rally (4)
Test and Tunes (10)
Vintage Events (11)
Please Select
Alfa Romeo Owners Club of Detroit
CSCC - Columbus (INDIANA) Sports Car Club
Central Ohio Rally Club
Champaign County Sports Car Club
Chicagoland Sports Car Club
Cincinnati Region SCCA
ClubFR, LLC
Connecticut Autocross and Rally Team
Corvette Club of Michigan
Detroit Council of Sports Car Clubs
Detroit Region SCCA
Fox Valley Region Porsche Club
Fox Valley Sports Car Club
Furrin Group Sportscar Club
GPS Track Time, LLC
Great Lakes Sports Car Club
Hampton Roads club MINI
JayCom Event Management
Lake Superior Region SCCA
Lakeshore Sports Car Club
MN Time Attack
MVSCC (Miami Valley Sports Car Club)
Madison Sports Car Club
Martin Sports Car Club
Michigan Sports Car Club
Michigan Turn Marshals
Midwestern Council of Sports Car Clubs
Minnesota Autosports Club
Minnesota Time Attack
NASA Florida
NASA Mid-Atlantic Autocross
NECC Motorsports (NECC)
NEPA Region SCCA
National Road Autosport LLC
Neohio SCCA
Northwoods Shelby Club
Ozark Mountain Region SCCA
Pennsylvania Hillclimb Association, PHA
Saginaw Valley Region SCCA
Sports Car Club of La Crosse
Sports Car Club of Rockford
Steel Cities Region SCCA
Suburban Corvettes of Minnesota
Susquehanna Region, SCCA
V-8 Estate Corvette Club Of Detroit
Virginia Motor Sport Club
Waterford Hills Road Racing, Inc.
Western Antique Aeroplane and Automobile Museum
Or perform an
Advanced Search
Site Information
Contact Us
Support Forums
Services & Pricing
Privacy Policy
Purchase Policy
Terms of Service
The page you have requested is available only to registered MyAutoEvents.com users.
Please Sign In or create a new account to continue.
Sign In to MyAutoEvents.com
New MyAutoEvents.com User
Returning MyAutoEvents.com User
I am a new user.
By creating an account at MyAutoEvents.com you will be able to register faster, stay up to date on event details, and keep track of the events you have entered and attended.
Creating an account on MyAutoEvents.com is FREE!
I am a returning user.
User Name
* Password is case sensitive.
Remember me on this computer
Can't remember your password? Click here.
Not a registered MyAutoEvents.com user?
Click here to create a new account
Can't remember your User Name or Password?
Click here to have your account information sent to your primary email address
MyAutoEvents.com is concerned about your privacy. Read the MyAutoEvents.com
Privacy Statement
to learn more.
Create Account
My Calendar
My Garage
My Profile
Organizer Tools
List your Organization
Publish an Event
Quick-Publish Events
Bulk-Upgrade Events
Copyright © 2002-2007 MyAutoEvents.com


text:
Cornmeal Porridge
|1 Quart
|1 Tablespoon
|Yellow cornmeal/White cornmeal
|2 2⁄3 Cup (42.67 tbs), finely ground
|4 Tablespoon, melted
1 In a heavy 2- to 3-quart saucepan, combine water and salt and bring to a boil over high heat.
2 Gradually pour the cornmeal into the boiling water, making sure that the boiling does not stops.
3 Keep stirring constantly with a wooden spoon to keep the mixture smooth.
4 Lower the heat and cover tightly.
5 Simmer for 10 to 12 minutes, or until the mamaliga is very thick and all the liquid in the pan has been absorbed.
6 Mound on a heated platter and moistened with the melted butter, serve at once.
Mamaliga may be served with meat and gravy as a substitute for bread or potatoes.
Or it may be served at room temperature as a separate course surrounded by black olives, hard-cooked eggs, dill and tarragon sprigs and accompanied by sour cream and brynza cheese.


text:
LaCie Sound2 Speakers launch
LaCie has announced what it says are "high-end speakers", modelled after acoustic engineering company Cabasse's loudspeaker technology - the LaCie Sound2 Speakers, as designed by Neil Poulton.
With Cabasse's loudspeaker driver support, the Sound2 Speakers are angled as ideal for use with computers, while the line-in means audio/video devices such as MP3 players and PMPs can also be plugged in.
Set-up is said to be easy via USB connection or the line-in port with no driver installation necessary. Complete with built-in USB cable and volume control, the Sound2 Speakers can provide 30 Watts total peak power output.
The LaCie Sound2 Speakers will be available through the LaCie Online Store, among others, for £89.


text:
The talent of Lonny Bereal is a throwback to an era of the complete entertainer. A time when artists not only had skills in the studio but most importantly could perform live and write their own songs. Lonny Bereal is destined to bring back that level of true artistry. Having started professionally as a background singer for the likes of Jamie Foxx, Tank, Kelly Rowland, Ruben Studdard, K-Ci & JoJo, Teddy Riley, Brandy, Monica, and a list of others, Bereal's exceptional vocal ability has kept him in demand. His range goes from tenor to soprano without a strain drawing comparisons to contemporaries like Brian McKnight and Maxwell. Over nearly a decade working in the music business, Bereal has skillfully and methodically developed himself into an award-winning songwriter and producer. A few of his most recent credits included: Chris Brown, Jamie Foxx, Keri Hilson and Keyshia Cole. Among the most notable hits he's written include Tank's"Please Don't Go" Pleasure P's "Under" and Chris Brown's "I Can Transform Ya." These gold and platinum successes have yielded other writing opportunities for Bereal on several top film soundtracks including "The Seat Filler", "Wifey," and the critically acclaimed Lebron James documentary "More Than A Game." Bereal earned an Emmy Nomination for music he created for the "Life Support" telefilm while he has also contributed songs to Tyler Perry's "Meet The Browns" and the top rated BET show "The Game."
Alas, with multiple Grammy Award Nominations and several ASCAP Songwriting Awards under his belt and a list of collaborators that reads like a 106 & Park Countdown, Bereal is ready to take center stage under the limelight. Signed by Notifi Records in 2011, on the strength of potential songs he'd written and sung for their artists Ginuwine and Johnny Gill, the label CEO Ira Dewitt was impressed by his fresh perspective as a songwriter and his full ranged, endearing vocal tone. The first glimpse of the amalgamation of Bereal's talents are on display on his first single, "Favor," a duet with superstar Kelly Rowland. Bereal originally wrote the song for singer, mentor and lil bro Chris Brown but is now using it to launch his own solo career. When thinking of a duet partner for the song Rowland immediately came to mind not only because Bereal has been friends with her for nearly a decade but serving as her longtime songwriter and vocal producer, he knew her sultry voice would bring the kind of sensuality the song demanded.
As Favor blast onto the radio charts at a faster clip than normal, Bereal and Rowland just finished shooting the sexy video for Favor which is due out soon. In the meantime, Bereal is holed up in the recording studio completing tracks for his forthcoming CD, The Love Train, due in late 2011. The album is an expression of love and relationships. It's almost a personal history of his own love life filled with pure and true emotions that are expressed over beautiful melodies and infections rhythms. In addition to Rowland, Bereal will be joined on The Love Train by other music luminaries such as Busta Rhymes, Trey Songz, Tank and Chris Brown. The disc will be executive produced by Ira Dewitt, Lonny Bereal, Kenny Bereal along with Troy Taylor who signed Trey Songz and has executive produced all his albums.
Lonny Bereal is a multi-award, multi-platinum singer, songwriter, and producer. 2012 Grammy Certificate winner, and ASCAP Top Song of the year winner. 2011, 2010, 2009, 2008, Grammy Award Nominee. 2007 ASCAP Songwriter of the year winner. And Emmy Award Nominee. Wrote over 65 hit songs for top recording artists in the music industry. Wrote #1 Billboard Urban AC song "Please Don't Go" performed by Tank Wrote #1 Billboard Urban song "Under" performed by Pleasure P. 2011 Released solo hit single "Favor" featuring Kelly Rowland. 2012 Released solo debut album titled "The Love Train." 2012 wrote hit singles "Wet the Bed" and "Strip" performed by Chris Brown. Performed at the 2013 Presidential Inauguration Ceremony for President Barak Obama. Co-wrote and vocal produced the Destiny's Child Reunion Album new single "Nuclear." 2013 ASCAP Top song of the year Award. 2014 Grammy Nominee.
Partial Film/TV Appearances & Tour List
Meet The Browns, The Seat Filler, Comic View, Mad TV. MTV. Pepsi Smash. I Heart Radio, Grammy Awards, Soul Train Awards, American Music Awards, Lady Of Soul Awards, Steve Harvey, One Night Stand. Chris Brown, Tank, Jamie Fox, Monica, TGT, Ruben Studdard, Kci & JoJo, Destiny's Child, Brandy, Trey Songz, 2003- Late Late show with Craig kiborn, American idol, 2004- Ellen DeGeneres, American idol, Tonight show with jay leno, Show time and the Apollo, 2005- tonight show with jay leno, American idol, Kelly, Ruben, and fantasia Home for Christmas, 2006-late show with David letterman, tonight show with jay leno. Fashion Rocks on BET, American music awards, The View, tonight show with jay leno, Tyra Banks show, 2010-52 annual Grammy awards, ACM aritst of the decade awards, 2014- Arsenio Hall Show


text:
Penny, WD; Kiebel, SJ; Kilner, JM; Rugg, MD; (2002) Event-related brain dynamics. TRENDS NEUROSCI , 25 (8) 387 - 389.
Full text not available from this repository.
Event-related potentials (ERPs) provide evidence of a direct link between cognitive events and brain electrical activity in a wide range of cognitive paradigms. It has generally been held that an ERP is the result of a set of discrete stimulus-evoked brain events. A recent study, however, provides new evidence to suggest that some ERP components might be generated by stimulus-induced changes in ongoing brain dynamics. This is consistent with views emerging from several neuroscientific fields, suggesting that phase synchronization of ongoing rhythms across different spatio-temporal scales mediates the functional integration necessary to perform higher cognitive tasks.
Archive Staff Only: edit this record